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SUMMARY 
Objective: This study was aimed at identifying Ghanaian traditional medicines used for the management of prostate 
diseases and their constituents. Reviews of studies conducted on them are also presented. 
Methodology: This was a prospective study. Traditional Medicine samples from consecutive patients with either 
lower urinary symptoms (LUTS) presenting at the Urology Unit of the Korle Bu Teaching Hospital (KBTH) in Ac-
cra from January 2015 to June 2016 and had a prior treatment with traditional medicines, had the samples retrieved. 
Additionally, all the 58 licensed pharmaceutical shops in Okaishie, a whole sale and retail depot for medicines in the 
main business district of Accra, were visited and traditional medicines for the management of prostate diseases ac-
quired. The products constituent as labeled were documented and entered once on a proforma. This study was part 
of a study on the management of benign prostate hyperplasia at the KBTH approved by the Medical Directorate. 
The findings were analyzed and presented using descriptive statistics and presented as a table. 
Results: Eleven products were identified with the main indigenous medicinal plant identified being the root extract 
of Croton membranaceus. This was the constituent in four products (Uro 500®, UR-Quick mixture®, Prostacure® 
and prostat®60). Although studies on the basic pharmacology and animal studies have confirmed its effect on the 
prostate, only one clinical study was identified.  
Conclusion: Croton membranaceus was the indigenous traditional medicine identified for relieving LUTS due to 
prostate disease. There is the need for empirical evidence on its efficacy in treating Prostate cancer.  
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INTRODUCTION 
Prostate diseases are common urological problems en-
countered by men in Ghana. The prevalence of moder-
ate to severe lower urinary symptoms due to benign 
prostate hyperplasia among the Ghanaian population 
(aged between 50 and 74 years) has been found to be 
19.9%1 and prostate cancer prevalence of 7% among 
men between 50 and 74 years.2,3  
 
There are various indigenous terms used to describe the 
condition when complicated by inability to void or acute 
retention of urine. Among the Gas in the southern 
coastal areas of Ghana this condition is referred to as 
‘Shamo baa’ which translated into English means, ‘the 
urine is not flowing’. Other tribes have different expres-
sions for inability to void due to prostate disease. In 
orthodox medical practice, various medications such as 
alpha-adrenergic blockers and 5 alpha-reductase inhibi-
tors have been used successfully to manage the lower 
urinary tract symptoms associated with prostate hyper-
plasia.  
 
In addition to refractory retention of urine (repeated 
urine retention) other complications from benign pros-
tate hyperplasia such as haematuria, recurrent urinary 
tract infections, bladder calculi and renal insufficiency 
are managed with surgical interventions such as open 
prostatectomy and transurethral resection of the pros-
tate.4 For the management of prostate cancer, patients 
who present early with local disease (cancer that had not 
spread) are offered either radical prostatectomy5,6 or 
radiation therapy (either as brachytherapy or external 
beam radiation therapy).  
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Anti-androgens such as flutamide or bicalutamide, syn-
thetic oestrogens (diethylstilboesterol) and luteinizing 
hormone releasing hormone (LHRH) agonist are used to 
manage patients presenting with locally advanced or 
metastatic disease.6  
 
For patients who cannot afford these agents, bilateral 
total orchidectomy is used even though most Ghanaian 
patients find it culturally unacceptable. For patients with 
locally advanced disease a combination of luteinizing 
hormone releasing hormone (LHRH) agonists and ex-
ternal beam radiotherapy is an alternate treatment re-
gime.6Currently in Ghana, alternate medicine has been 
incorporated into the main stream medical services. As 
a result, more patients are resorting to Traditional Medi-
cine to address their ailments including prostate condi-
tions.  
 
Other reasons for the increase in herbal medicine use in 
underdeveloped countries has been attributed to such 
factors as the high cost of pharmaceutical medicines and 
overcrowding of patients in clinics and hospitals.7 A 
study found that low-income levels, being a trader, per-
ceiving traditional medicines as effective and safe, good 
affective behavior of traditional medicinal practitioner 
and having chronic ill health as predictors of utilization 
of traditional medicines among Ghanaians.8  
 
Herbal medicine, botanical medicine or phytomedicine 
refers to using plant components such as seeds, berries, 
roots, leaves, bark, or flowers for medicinal purposes.9 
It has been noted that Traditional Medical practice has 
long been used outside of conventional medicine but 
mainly for primary health care.  
 
However, its use in Ghana has been extended to involve 
more tertiary conditions such as prostatism due to be-
nign prostate hyperplasia (BPH) and prostate cancer.10 
Phytotherapeutic agents have been noted to have at-
tracted tremendous attention for the treatment of BPH 
and prostate cancer, because they are thought to be saf-
er, more cost-effective, and have fewer side effects than 
conventional alternatives. 11,12  
 
Another reason for increased patronage has been at-
tributed to improvements in analysis and quality control 
along with quality clinical research supporting the value 
of herbal medicine in the treatment and prevention of 
diseases. The use of herbal medicine has been reported 
to be on the increase in many developing and industrial-
ized countries.13,14 
 
The World Health Organization (WHO) estimates that 
four billion people (about 80 percent of the world popu-
lation) use herbal medicine for some aspect of primary 
health care. 15,16,17 In Ghana 75% of the population are 
said to depend on traditional herbal medicine for their 
healthcare. 18,19 The WHO encourages developing coun-
tries to supplement their health programs with tradition-
al herbal preparations provided they are proven to be 
non-toxic.20 
 
The Center for Research into Plant Medicine (now Cen-
ter for Plant Medicine Research CPMR) in Ghana was 
established in 1975 by the Government of Ghana in 
recognition of the pioneering work of Dr. Oku Ampofo, 
a Ghanaian allopathic medical practitioner. Its mandate 
was to identify and characterize Ghanaian herbs with 
medicinal properties to support their use in a more sci-
entific and evidence-based manner. 
 
Ghana has a rich biodiversity and rich tradition of plant 
medicine in various forms and has an enormous number 
of indigenous medicinal plants. Traditional medicines in 
Ghana range from individual one-product, home-made 
product, to family-size and occasionally large scale pro-
duction where the products are distributed and sold in 
Chemical and Pharmacy shops in the country. 8 
 
As noted earlier, Ghana has a dual system of medical 
practice that recognizes both traditional and orthodox 
medical practices in law and promotes their co-
existence. This is intended to allow access by the great-
est number of citizens 21, thus there is inclusion of some 
traditional medicinal products in Ghana’s essential drug 
list.  
 
This new development stems from the fact that Tradi-
tional Medicine services are often affordable and acces-
sible to the vast rural population and therefore serve as a 
forerunner in the primary medical care of the popula-
tion. The model of integrating traditional herbal practice 
into the mainstream health system was commenced in 
2010 and was based on WHO recommendations and in 
line with country-specific studies and observations.  
 
The Ministry of Health/ Ghana Health Service (MOH / 
GHS) initiated the policy on institutionalizing herbal 
medicine services on pilot bases. Allowing graduate 
traditional herbal practitioners from the tertiary institu-
tions to practice side by side with their orthodox practi-
tioners with the added advantage of each being able to 
make referral (either way) for further management as 
found appropriate.   
 
The drugs used were procured from Central Medical 
Stores (CMS) and Center for Plant Medicine Research 
in Ghana based on a Ministry of Health medicinal list.  
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However, some of the products are pending registration 
with the Ghana Foods and Drugs Authority, the body 
mandated to certify all medications used in the country. 
In a review of this current initiative, it was observed that 
the acceptability of the integration of the herbal and 
orthodox systems was 94.4% among core hospital staff.  
 
The stated reasons for acceptability included it boosting 
confidence in herbal medicines, streamlining traditional 
practice, reducing pressure on orthodox care/ practice 
and ensuring the use of only herbal medicines approved 
by the regulatory body (Food and Drugs Authority).  
 
The clinical staff that found the integration unacceptable 
were concerned that the move will lead to a perception 
of endorsement of 'quack' herbal practitioners.22 In this 
era of evidence-based medicine, some of these health 
professionals find it difficult to accept historical and 
empirical evidence as the only necessary criterion for 
herbal medicine’s efficacy. 
 
Prostate diseases are common urological problems en-
countered by men in Ghana. In line with the current 
incorporation into the mainstream medical services of 
traditional medicines, more patients are resorting to 
Traditional Medicine to address their ailments.8 This 
includes prostate conditions.  
 
In our experience some patients request to be offered an 
option of traditional medicine in the normal urology 
clinics for prostate diseases. (Personal communications) 
Knowledge of the currently available traditional medi-
cines for the management of prostate disease will equip 
practicing Urologists and Medical practitioners to ena-
ble them to appropriately counsel patients on the use of 
these medications. 
 
This study was aimed at identifying the Ghanaian tradi-
tional medicines used for the management of symptoms 
related to prostate diseases, the constituents of the herb-
al products that were indigenous and their pharmacolo-
gy. Also considered are studies that have been conduct-
ed on these products both animal and clinical. Areas of 
concern in the use of these herbal products as well as 
areas needing further research are highlighted. 
 
METHODS 
This was a prospective study. Traditional Medicine 
samples from consecutive patients presenting at the 
Urology unit of the Korle Bu Teaching Hospital in Ac-
cra (a major referral center for Southern Ghana) from 
January 2015 to June 2016 who complained of either 
obstructive or irritative lower urinary tract symptoms or 
its associated complications and had a prior treatment 
with traditional medicines, and consented either by sign-
ing or thumb printing a consent form depending on the 
educational status had the samples retrieved.  
 
Once a product was identified and retrieved, that prod-
uct was not retrieved again. Seven products were identi-
fied this way from 5 patients with age range of 54 to 73 
years. Additionally, all the 58 licensed pharmaceutical 
shops in Okaishie drug stores lane, a wholesale and re-
tail depot for medicines including traditional medicines 
in the main business district of Accra were visited. 
Those with stocks of traditional medicines for the man-
agement of prostate diseases had the medicines ac-
quired. The products constituents as labeled were doc-
umented. Okaishie was chosen as it is a wholesale and 
retail depot for medicines including traditional medi-
cines in the main business district of Accra.  
 
The products identified were compared to the medicines 
retrieved from the patients in order to ensure that all 
available medicines had been accounted for. This was 
supplemented with the monitoring of radio broadcast 
advertisements on three popular radio stations in Accra, 
from Monday to Friday 7.00am to 12 noon each day 
from January 2016 to June 2016 in order to identify 
additional products. Each product was entered once in a 
proforma. The products constituent as labeled were 
documented.  
 
This data was obtained as part of the clinical component 
of the Survey of Prostate Cancer in Accra with ethical 
clearance by the University of Ghana (Noguchi Memo-
rial Institute for Medical research) ethical review board.  
Traditional medicines intended to be used for treatment 
of prostate diseases which did not have the constituents 
indicated on the labels were excluded from the study.  
 
Data Analysis 
The findings were analyzed and presented using de-
scriptive statistics and presented as a table. The indige-
nous constituents identified formed the basis of a litera-
ture search using PubMed and Google scholar data ba-
ses. Additionally, visits were made to the CPMR at 
Mampong-Akwapim to determine studies, animal and 




A total of 11 products were identified that had the man-
agement of prostate diseases as their main indication 
however, 3 were excluded as the labels did not indicate 
their constituents. (Table 1).  
 
Seronoa repens and Saw Palmetto which are some of 
the main stay in the phytotherapy for lower urinary tract 
symptoms due to BPH were the constituents of four of 
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the herbal preparations – Prostavite mixture®, Prostate 
care herbal capsules®, Prostate health® and Freemax 
prostate cure® which also contained nettle root.  
These are not indigenous plants in Ghana but the con-
stituents are imported for the formulations.   
 
Table 1 Traditional medicines for management of prostate diseases and their constituents 
Serial 
No. 
Trade name  Formulation/ 
Description 
Constituents as per label 
1 Uro 500® Capsule  Croton membra-
naceus 
    
2 Prostavite mix-
ture® 
Liquid  Barosma betulina Serenoa repens Silybum marianum herbal extracts  
3 Prostate care 
herbal capsules®  
Capsule  Saw palmetto small flowered 
willow herb 
stinging nettle pau darco Buchu 
4 Prostate health® Capsule  Saw palmetto pumpkin seed    
5 UR-Quick Mix-
ture® 
Liquid  Croton membra-
naceus 
Antaeus Africana Cnestis ferruginea   
6 Prostacure® Liquid   Croton membra-
naceus 
    
7 Freemax prostate 
cure® 
Capsule  Seronoa serrulata nettle root    
8 Prostat 60® Capsule Croton membra-
naceus 
Anona muricata    
The main indigenous medicinal plant used for the man-
agement of prostate diseases in Ghana is the root extract 
of Croton membranaceus Mull. Arg. (Euphorbiaceae) 
[C. membranaceus], which was a constituent in four of 
the products. It has been observed to relieve symptoms 
of BPH and enhance urination without the accompany-
ing difficulty. It is marketed as URO 500® with 10mg 
oral formulation of the plant by weight. The product is 
packaged by the CPMR. This plant was found in three 




The interest in the Ghanaian indigenous plant C. mem-
branaceus in the management of prostate diseases 
(found in four of the products - Uro 500®, Prostat 60®, 
Uro-Quick® mixture and Prostacure®) has led to various 
laboratory studies to identify the active constituents. 
Both animals and human studies aimed at understanding 
the underlying mechanism of its action and its clinical 
effectiveness has been conducted.  
 
Basic constituents/pharmacology of Croton membra-
naceus 
A study by Aboagye FA showed that C.membranaceus 
inhibited the enzyme activity of 5α-reductase in rat 23 
serum leading to a reduction in the levels of dihydrotes-
tosterone levels in vitro however no significant reduc-
tions in the serum levels of dihydrotestosterone was 
observed in vivo.  
 
This led him to conclude that inhibition of 5α-reductase 
activity may not be the major mechanism by which the 
extract exerts its action on patients with LUTS due to 
BPH.23 Thus the exact mechanism of action of the C. 
membranaceus is yet to be established. 
 
The compound Julocrotine, a glutarimide alkaloid has 
been isolated from the plant.24 A study by Baylor et al. 
identified a cytotoxic diterpenoid from C. membra-
naceus which was felt could underlie claims of its use 
for cancer treatment.25 A methanolic extract of the roots 
has also been shown to have cytotoxic activities against 
two cancer cell lines.26 A bioassay-guided fractionation 
of this extract revealed that the cytotoxic activity resid-
ed mostly in the ethyl acetate fraction. Six compounds 
were isolated from this fraction, including a furano-
clerodane diterpenoid, for which the name crotomem-
branafuran was suggested.26 This compound exhibited 
an IC50 value of 4.1 µg/mL (10.6 µM) against human 
prostate cancer (PC-3) cells, which might provide some 
support for the traditional use of C. membranaceus in 
the treatment of cancers.26  
Original Article  
 
                                                                                                                                                                               
www.ghanamedj.org  Volume 51 Number 3 September 2017 132 
These findings are important as the use of the herbal 
medication for the treatment of prostate cancer consid-
ered a tertiary care disease is being practiced. However, 
it's clinical efficacy in treating prostate cancer is yet to 
be ascertained.  
 
Formulation of Croton membranaceus 
Various formulations of the root extract is available; 
ethanol extracts (liquid, tablets and capsules) and aque-
ous extracts (liquid). Bayor et al. demonstrated that the 
oral capsule was the most appropriate dosage form for 
C. membranaceus. In their study, they formulated both 
liquid and solid oral dosage forms from the ethanol ex-
tract of C. membranaceus27 root and investigated their 
physicochemical properties, release effects and suitabil-
ity in comparison with aqueous decoctions and unfor-
mulated powdered plant material.  
 
They observed that the ethanol extract had characteris-
tics similar to the aqueous decoction, but unlike the lat-
er, it maintained its specifications and stability through-
out the period of study. The use of large volumes, con-
venience and short shelf life, was said to limit the appli-
cation of aqueous decoctions. The assessed properties of 
the prepared tablets and capsules met all the specifica-
tions required for good quality and had the advantage 
that it could be used in simple and convenient doses of 
one tablet or capsule, three times a day, in place of un-
stable decoctions and large volume solutions.  
 
They also observed that the in vitro release profile of the 
capsules was however, better and significantly higher 
than that of the tablets. They concluded that oral cap-
sules should be the preferred choice of solid dosage 
form for C. membranaceus and that its use will ensure 
compliance and maximize therapeutic outcomes.27 
While Uro 500® and Prostat 60® were capsules, Uro-
Quick® mixture and Prostacure® (powder)were admin-
istered as aqueous decoctions. 
 
Animal studies on Croton membranaceus 
Various animal studies have been performed on C. 
membranaceus. In a study by Afriyie et al on the treat-
ment of BPH with C. membranaceus in an experimental 
animal model, they set out to evaluate if C. membra-
naceus root extract could attenuate the development of 
BPH in adult male Sprague-Dawley rats.28 Though they 
did not find statistical difference in prostate size in those 
receiving C. membranaceus root extract, there was at-
tenuation of the growth of the stromal and epithelium 
cells. This finding was similar to the use of finasteride 
(a 5-alpha reductase inhibitor) in a comparable group 
with an associated shrinkage of the prostate.28 Notewor-
thy was lowering of the prostate specific antigen in the 
group.  
As noted, an earlier study that sort to determine if C. 
membranaceus led to reduction in dihydrotestosterone 
levels in rat serum, found it to inhibit the synthesis of 
dihydrotestosterone by prostatic 5α-reductase in the rat 
in vitro, but did not confirm that C. membranaceus had 
significant effect in lowering dihydrotestosterone levels 
in vivo. 23 
 
Another study evaluated Mitochondria-dependent apop-
togenic activity of aqueous root extract of C. membra-
naceus against human BPH-1 cells 29 and found that C. 
membranaceus root extract induced a significant dose- 
dependent inhibition in the proliferation of BPH-1 cells 
with significant DNA fragmentation, and the induction 
of mitochondria- dependent apoptosis of the BPH-1 cell 
lines.29 
 
Clinical studies on use of Croton membranaceus 
Only one observational clinical study on the use of C. 
membranaceus on clinical BPH has been published to 
date. In a study of 33 patients presenting with lower 
urinary symptoms due to BPH, but with 30 of them 
completing the study, Asare et al showed that a freeze-
dried C. membranaceus ethanol root extract adminis-
tered orally at a dose of 20mg eight hourly for 3 months 
led to an improvement in the international prostate 
symptoms score with a shift from severe lower urinary 
symptoms to moderate to mild symptoms.10  
 
The tools used in this observational study were the In-
ternational prostate symptoms score (IPSS), Internation-
al index of erectile function and abdomino-pelvic ultra-
sound to determine prostate size and post void residual 
urine volume. The proportion of patients with severe 
symptoms reduced from 37% to 0% while the propor-
tion with mild symptoms increased from 23% to 43%. 
Those with moderate symptoms however increased 
from 40% to 57%.  
 
Thus, although there was improvement in those with 
severe symptoms there still remained a significant num-
ber of them with moderate symptoms (IPSS 9-19) which 
raises issue about the effectiveness of the C. membra-
naceus extract. Reduction in prostate size (shrinkage) 
was also observed in the study, with the mean prostate 
volume decreasing from 101.8 to 54.5grams.  This re-
duction in the glandular weight reflects a reduction in 
possible glandular components.  
 
However, its effect on prostate smooth muscle activity 
(ie relaxation) was not accessed. Similarly, uroflow rate 
using an uroflowmeter as an objective means of estab-
lishing reduction in bladder outlet resistance was not 
accessed in this observational study.  Also, prostate size 
determination was by way of an abdominopelvic ultra-
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sound as against the use of transrectal ultrasound which 
has been noted to give a more accurate determination of 
prostate volume. 
 
A large study with a relatively long duration of treat-
ment and with the inclusion of uroflowmetry measure-
ment is needed to ascertain the long-term efficacy of the 
C. membanaceus in clinical practice.  Though there was 
derangement in liver function observed based on in-
creases in total and indirect bilirubin as well as apolipo-
protein they were not associated with clinical symp-
toms.10 Effect on these parameters with longer term use 
need to be examined.   
 
C. membranaceus has been used as a traditional medi-
cine for the treatment of prostate cancer. Animal studies 
have indicated its cytotoxic effect on BPH-1 cell lines 
as well as C. membranaceus promoting apoptosis.29 
Another important observation is the associated reduc-
tion of the serum prostate specific antigen (PSA) both in 
animal studies 28 and human clinical studies. 10 Reduc-
tion in PSA level though observed in the use of 5-alpha 
reductase, is an important marker of the clinical effec-
tiveness of anti-prostate cancer agent such as anti-
androgens and luteinizing hormone releasing hormone 
agonist. This has led to a suggestion supporting its use 
as traditional medicine for the management of prostate 
cancer.25 
 
Despite these observations, no clinical studies have been 
conducted on the use of C. membranaceus in the man-
agement of prostate cancer either to achieve cure or to 
reduce its progression. Observations at urology clinics 
find that patients with prostate cancer on C. membra-
naceus present with advanced and metastatic disease 
despite having been on this traditional medicine treat-
ment for considerable period of time.   
 
Toxicity/ Side effects and caution on use of Croton 
membranaceus 
Toxicity studies on C. membranaceus in animals identi-
fied no toxicity to the major organs of the body.30 Of 
interest is an advantage of it being potentially anti-
atherogenic and anti-ischemic.31 No adverse biological 
effect has been noted in other studies.32,33 In the clinical 
study on its use in BPH, there were no observable ad-
verse effects associated with the clinical use of prepara-
tions of C. membranaceus during the study period of 
three months. However, the liver function tests had 
some parameters increasing slightly with a statistically 




Pharmacovigilance must be heightened if these products 
are used in order to identify side effects not seen in the 
aforementioned studies which involve small numbers of 
subjects and a short duration of follow-up.  
 
Variations in constituents of traditional herbal medi-
cines have been of concern. It has been noted that the 
widespread disregard for quality control in the health 
food industry has brought into disrepute many important 
medicinal herbs. Herbal medicines, as they are now 
prepared in Ghana, contain varying levels of active con-
stituents. Some medicines may have high levels of ac-
tive constituents and thus lead to over- dose while oth-
ers may have little or no active constituents at all, and 
may at best be described as placebos.8 Without proper 
quality control, there is no assurance that the herbal 
product contained in the bottle is the same as what is 
stated on the label.34 Standardization must therefore be 
pursued.  
 
Bacteria contamination of products has also been of 
concern. In a study by Ampofo et al7, thirty-one herbal 
preparations produced from different processing com-
panies and sold on the Ghanaian market were randomly 
purchased from sales outlets and analyzed for their mi-
crobiological quality by testing for the presence of total 
coliform bacteria, faecal coliform bacteria, and total 
heterotrophic bacteria count.  
 
They also looked for pathogenic bacteria such as the 
Salmonella spp. and Clostridium spp as well as oppor-
tunistic bacterial pathogens (Aeromonas spp., Entero-
coccus spp. and Pseudomonas spp.) and mould. Of in-
terest in the findings is the fact that herbal preparations 
tested included some indicated for treatment of urine 
retention.  
 
After culturing aliquots of the various herbal products 
on various selective media, twenty-six (26) of the prod-
ucts had pathogenic bacteria contamination and in par-
ticular eight of the products showed the presence of all 
microorganisms analyzed for and they recommended 
those products should not be used.7 These findings need 
to be noted while recommending these herbal products 
for the treatment of symptoms of benign prostate hyper-
plasia.  
 
Traditional Medical Practitioners engaged in the 
management of prostate diseases 
In Ghana, it is estimated that the ratio of traditional 
medical practitioners (TMPs) to the population is 1: 
400.35,36 This group is a heterogeneous one with differ-
ent categories of healers. They include bonesetters and 
herbalists who specialize in the use of herbs and plants, 
with or without fetish (or spirits) in treating patients.  
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It has been observed that each village has its traditional 
practitioner who uses local plant remedies and in many 
cases rituals as well, to achieve healing for the popula-
tion.  
The TMPs have been noted to play a very important role 
in health delivery in the rural areas where there is less 
access to orthodox facilities with 70 -80% of Ghanaians 
using traditional medicines.18,19 Its importance in Ghana 
is attributed to the fact that a number of Ghanaians be-
lieve that some diseases are not curable with orthodox 
western medicines.  
 
The combination of mystical powers and the herbs is 
believed to offer a more lasting solution or cure for 
some of these diseases. Formal training in the use of 
traditional herbal medicines has been institutionalized in 
some of the tertiary institutions in Ghana. These gradu-
ates have also set up various 'scientific' herbal clinics 
that are apparently using more standardized remedies in 
their traditional medicine practice. This group has been 
noted not only to manage the primary health care dis-
eases but also tertiary care ones such as hypertension, 
diabetes mellitus and prostate diseases.   
 
Another category of practitioners are those who have 
undergone formal orthodox medical training who have 
veered into the practice of traditional medicine. These 
operate a hybrid practice with a combination of both 
orthodox medical care with the requisite supporting 
investigations and the use of traditional medicinal rem-
edies. However, their practice has been called into ques-
tion due to their empirical use of these traditional medi-
cines to treat prostate diseases without differentiating 
between benign and malignant prostate diseases with 




To safe guard the health of the Ghanaian population, 
laws have been enacted to establish regulatory bodies to 
help ensure proper practice of alternate medicine. The 
regulatory bodies thus established include the Foods and 
Drugs Board, the Traditional Medicine Practice Council 
and the CPMR.  The Ghana Medical and Dental Council 
may need to play a regulatory role in the current hybrid 
system and the process of integration of alternate medi-
cine into the mainline orthodox medical services.  
 
The mandate of these regulatory Bodies is to ensure a 
rational use of herbal and plant medicines that are of 
proven efficacy and safe and to achieve an overall ethi-
cal herbal medical practice. The  history of the process 
of recognizing and formalizing traditional remedies in 
Ghana dates back to 1961 with the formation of the 
Ghana Psychic and Traditional Healing Association, the 
establishment of the Centre for Scientific Research into 
Plant Medicine in 1975, the institution of the Direc-
torate of Herbal Medicine in the Ministry of Health in 
1991 and in 1997 the setting up of the Food and Drug 
Board under the Food and Drugs Law  of 1992 (PNDC 
Law 305b) to regulate and control the commercializa-
tion of food and drug products (including traditional 
medicinal products). A Traditional Medicine Practice 
Act, Act 575 (Feb. 2000) has been enacted to give legal 
backing to the regulatory process.   
 
There is the need to streamline the activities of these 
regulatory bodies to fall in line with current trends and 
evolution of alternate medical practice particularly in 
this era of proliferation of mass media outlets offering 
unsubstantiated claims of efficacy and safety of some 
herbal products.  
 
Current practice in the use of Traditional Medicines 
for the treatment of prostate diseases 
The current traditional medical practice in the treatment 
of prostate diseases does not differentiate between pros-
tatitis, benign prostate hyperplasia and prostate cancer 
with the herbal remedies being advocated for sympto-
matic relief in all these conditions.  
 
A prevalence of prostate cancer of about 7 % in the 
Ghanaian population 2,3 raises the possible risk of over-
looking a prostate cancer if no attempt is made to under-
take further investigations that will allow the diagnosis 
of prostate cancer when present and also provide appro-
priate and effective treatment.  
 
The optimal management of BPH is equally important 
because if not managed appropriately complications 
such as haematuria, renal insufficiency from obstructive 
uropathy, and recurrent urinary tract infections leading 
to urosepsis may ensue which could be life threatening. 
The use of the traditional medicines for the management 
of prostate diseases among orthodox medical practition-
ers has been minimal as they are observed with suspi-
cion. The recent observational clinical study on the use 
of C. membranaceus in patients with lower urinary 
symptoms due to BPH 10 should pave the way for a 
larger study (enrolling more patients) that will help de-
fine the patient population that will benefit most, and 
thus allow for a more targeted use of the product. The 
efficacy of the product in such a large study as judged 
by its effect on the international prostate symptoms 
score (IPSS) [mild, moderate and severe], the quality of 
life score, the peak flow rate, and the post void urine 
volume, will help identify the category of patients that 
will benefit the most. 
 
Original Article  
 
                                                                                                                                                                               
www.ghanamedj.org  Volume 51 Number 3 September 2017 135 
To the best of our knowledge, no clinical study has been 
performed on the use of C. membranaceus for prostate 
cancer treatment. There is therefore the need to clinical-
ly differentiate BPH and prostate cancer to allow for 
targeted management.  
The blanket use of this medication and others to treat 
prostate diseases including prostate cancer has the po-
tential to lead to under treatment of an underlying pros-
tate cancer that may result in a potential threat to life.  
 
Future research requirements 
As stated earlier, clinical research needs to be conducted 
to determine the efficacy of C. membranaceus on vari-
ous prostate diseases to allow for a more targeted treat-
ment. This will also assist in the evaluation of the effi-
cacy of these traditional medicines compared to the 
more conventional orthodox medications. Further safety 
studies need also be conducted on C. membranaceus.  
 
As reduction in PSA has been noted with the use of C. 
membranaceus, effect on fertility need to be ascertained 
especially as it is administered for lower urinary symp-
toms without any consideration of age and future fertili-
ty aspirations. Also of interest is possible interaction of 
these traditional medicines with other medications. This 
is of importance as the integration of these traditional 
medicines into the routine management of prostate dis-
eases is now in effect. 
 
CONCLUSION 
There are both animal and human studies to support the 
effectiveness of C. membranaceus in the management 
of some patients with lower urinary symptoms due to 
BPH.  What remains to be elucidated is the population 
subgroup with lower urinary tract symptoms due to 
BPH in whom C. membranaceus will achieve satisfacto-
ry results with respect to good urine flow rates and ac-
ceptable post void residual urine volume levels. This 
will require a large study population to establish.  While 
its medicinal significance has generated scientific inter-
est in the plant there is real concern in relation to the 
longer-term availability of this indigenous plant in its 
natural habitat.  
 
The clinical effectiveness of C. membranaceus for the 
management of prostate cancer has not been established. 
There is therefore the need to carry out further studies to 
validate its use among traditional medical practitioners 
in Ghana in managing all prostate diseases including 
prostate cancer.  Until this is done, efforts must be made 
to educate users of this plant product of the fact that 
symptoms of prostate cancer and BPH are often indis-
tinguishable. Every effort must therefore be made at 
initial evaluation to ensure that those with possible un-
derlying prostate cancer are referred for appropriate 
diagnosis, staging and treatment. 
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